Compare NAK & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAK | CCCC |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | Canada | United States |
| Employees | 12 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.3M | 363.7M |
| IPO Year | 2002 | 2020 |
| Metric | NAK | CCCC |
|---|---|---|
| Price | $0.41 | $2.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | ★ 4.2M | 2.7M |
| Earning Date | 12-01-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $0.51 | $1.69 |
| 52 Week High | $2.66 | $5.17 |
| Indicator | NAK | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 21.72 | 34.70 |
| Support Level | N/A | $2.47 |
| Resistance Level | $1.79 | $3.25 |
| Average True Range (ATR) | 0.06 | 0.23 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 0.00 | 16.75 |
Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.